Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Operating Leases (2022 - 2025)

Historic Operating Leases for Day One Biopharmaceuticals (DAWN) over the last 4 years, with Q3 2025 value amounting to $2.7 million.

  • Day One Biopharmaceuticals' Operating Leases rose 764.38% to $2.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.7 million, marking a year-over-year increase of 764.38%. This contributed to the annual value of $2.6 million for FY2024, which is N/A changed from last year.
  • Latest data reveals that Day One Biopharmaceuticals reported Operating Leases of $2.7 million as of Q3 2025, which was up 764.38% from $2.8 million recorded in Q2 2025.
  • Day One Biopharmaceuticals' 5-year Operating Leases high stood at $2.9 million for Q1 2025, and its period low was $77000.0 during Q3 2023.
  • Moreover, its 4-year median value for Operating Leases was $617000.0 (2022), whereas its average is $1.4 million.
  • In the last 5 years, Day One Biopharmaceuticals' Operating Leases crashed by 8501.95% in 2023 and then skyrocketed by 319610.39% in 2024.
  • Over the past 4 years, Day One Biopharmaceuticals' Operating Leases (Quarter) stood at $408000.0 in 2022, then tumbled by 81.13% to $77000.0 in 2023, then skyrocketed by 3266.23% to $2.6 million in 2024, then grew by 5.4% to $2.7 million in 2025.
  • Its Operating Leases stands at $2.7 million for Q3 2025, versus $2.8 million for Q2 2025 and $2.9 million for Q1 2025.